Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment”

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company specializing in developing novel treatments for brain tumors, has focused on its lead drug candidate, Berubicin, to potentially treat glioblastoma (“GBM”). “CNS has since made significant headway, even receiving FDA Fast Track Designation, which now offers it an accelerated path to approval for Berubicin. ‘With this … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients”

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM”